Otomycosis
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
SalvatFL - Miami
3 programs3
G238Phase 31 trial
SVT-15652Phase 31 trial
SVT-15652Phase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SalvatSVT-15652
SalvatSVT-15652
SalvatG238
Clinical Trials (3)
Total enrollment: 601 patients across 3 trials
SVT-15652 Otic Solution for the Treatment of Otomycosis.
Start: Jun 2020Est. completion: Oct 2021194 patients
Phase 3Completed
SVT-15652 Otic Solution for the Treatment of Otomycosis
Start: Feb 2020Est. completion: Oct 2021217 patients
Phase 3Completed
Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
Start: May 2013Est. completion: Nov 2014190 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space